Agilent Technologies (NYSE:A) Now Covered by Analysts at Rothschild & Co Redburn

Key Points

• Rothschild & Co Redburn has initiated coverage of Agilent Technologies, assigning a "buy" rating with a target price of $165.00, suggesting a potential upside of 19.08% from the previous close.
• Agilent's stock has received various upgrades from different analysts, with the consensus rating currently being a "Moderate Buy" and a target price of $144.85.
• In the last quarter, Agilent posted earnings of $1.37 per share, meeting estimates, and reported revenue of $1.74 billion, exceeding expectations and reflecting a 10.1% year-over-year growth.

Investment analysts at Rothschild & Co Redburn began coverage on shares of Agilent Technologies (NYSE:A - Get Free Report) in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage set a "buy" rating and a $165.00 price target on the medical research company's stock. Rothschild & Co Redburn's target price would indicate a potential upside of 19.08% from the company's previous close.

A has been the topic of a number of other research reports. Robert W. Baird boosted their price objective on Agilent Technologies from $141.00 to $142.00 and gave the stock an "outperform" rating in a research note on Thursday, August 28th. Wells Fargo & Company boosted their price objective on Agilent Technologies from $140.00 to $150.00 and gave the stock an "overweight" rating in a research note on Monday, September 15th. Barclays boosted their price objective on Agilent Technologies from $125.00 to $150.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 2nd. Wall Street Zen raised Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Friday, October 3rd. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Agilent Technologies in a research note on Saturday, September 27th. Seven analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $144.85.

Agilent Technologies Stock Down 2.2%

Shares of Agilent Technologies stock opened at $138.56 on Wednesday. The business's fifty day moving average price is $123.61 and its two-hundred day moving average price is $116.64. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The company has a market capitalization of $39.28 billion, a P/E ratio of 32.53, a PEG ratio of 4.62 and a beta of 1.26. Agilent Technologies has a 1-year low of $96.43 and a 1-year high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last announced its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting the consensus estimate of $1.37. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm's revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, research analysts forecast that Agilent Technologies will post 5.58 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of A. Brighton Jones LLC grew its holdings in shares of Agilent Technologies by 6.1% during the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock valued at $626,000 after buying an additional 270 shares in the last quarter. Merit Financial Group LLC grew its holdings in shares of Agilent Technologies by 56.3% during the first quarter. Merit Financial Group LLC now owns 4,348 shares of the medical research company's stock valued at $509,000 after buying an additional 1,567 shares in the last quarter. Capital Investment Advisors LLC grew its holdings in shares of Agilent Technologies by 42.3% during the first quarter. Capital Investment Advisors LLC now owns 2,809 shares of the medical research company's stock valued at $329,000 after buying an additional 835 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Agilent Technologies by 34.6% during the first quarter. GAMMA Investing LLC now owns 5,362 shares of the medical research company's stock valued at $627,000 after buying an additional 1,379 shares in the last quarter. Finally, Fiduciary Financial Group LLC purchased a new position in shares of Agilent Technologies during the first quarter valued at $318,000.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.